Topic
How have GLP-1s changed everyday culture?
How GLP-1s changed food, celebrity, work and the American economy.
Celebrities on Mounjaro and Zepbound: A Sourced ListA list of public figures who have said, in their own words, that they used tirzepatide - either Mounjaro or Zepbound - with the date, the outlet and what they actually said, plus a clear line between unpaid disclosures and paid brand partnerships.Celebrities on Ozempic: A Sourced ListA documented list of public figures who have said on the record that they used a GLP-1 drug, with the exact drug where they named it, the date, and the quote - and a note on why speculation about everyone else does not belong here.How Eli Lilly's GLP-1 Boom Changed IndianapolisTirzepatide turned a 150-year-old Indianapolis drugmaker into the most valuable health care company on earth, and the money landed on one state. Here is what Lilly's GLP-1 boom has actually done to Indiana jobs, wages, taxes, construction and philanthropy - and what the risks are.How Many Americans Take GLP-1 Drugs: The NumbersGallup puts current GLP-1 use for weight loss at 11% of US adults and KFF puts current use for any reason at 12%, and this guide explains what those numbers count, how fast they grew, and who is actually taking the drugs.How Many Americans Take Zepbound or Mounjaro: The NumbersNo survey publishes a clean count of US Zepbound or Mounjaro users, so this guide assembles what is actually measured - prescriptions, revenue, market share and poll numbers - and explains what each one does and does not tell you.How Ozempic Changed American CultureIn four years a diabetes brand became American shorthand for thinness, rewrote how we talk about appetite and willpower, and reshaped everything from Oscar monologues to grocery aisles - here is what actually changed and what the evidence shows.How Zepbound Overtook WegovyZepbound launched two years after Wegovy and passed it in new prescriptions within about three months. This is the sourced story of how tirzepatide took the US weight-loss market, told through prescription data, a head-to-head trial, a cash-price war, one enormous insurance decision and a lawsuit.Ozempic and Eating Disorders: The DebateGLP-1 drugs quiet appetite, which is exactly what makes clinicians who treat eating disorders uneasy - here is what the research actually shows, where experts disagree, and what the professional guidance says about screening.The GLP-1 Economy: Who Wins and LosesGLP-1 drugs are reshaping grocery baskets, restaurant menus, clothing sizes, gym memberships and airline fuel bills - here is what the spending data actually shows about which industries gain and which shrink.